Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

Shocking revelations from a Federal Trade Commission, or FTC, investigation have exposed how three major prescription benefit managers, or PBMs, ...

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

FTC’s report focused on three largest PBMs ... A transformation in the PBM space will likely lead to fairer pricing and improved access to essential medications for customers, ultimately ...

HB1150 would ban the around 35 PBM-owned pharmacies in the state and prevent over 100 out-of-state PBM-owned pharmacies from ...